Beclabuvir

• CAT Number: I005682
• CAS Number: 958002-33-0
• Molecular Formula: C36H45N5O5S
• Molecular Weight: 659.84
• Purity: ≥95%
• Target: HCV
• Solubility: DMSO: ≥ 30 mg/mL
• Storage: Store at -20°C
• IC50: < 28 nM (NS5B protein)
• IUPAC Name: (8S,10R)-19-cyclohexyl-N-(dimethylsulfamoyl)-5-methoxy-10-(3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-12-azapentacyclo[10.7.0.02,7.08,10.013,18]nonadeca-1(19),2(7),3,5,13(18),14,16-heptaene-15-carboxamide
• InChI: InChI=1S/C36H45N5O5S/c1-38(2)47(44,45)37-34(42)23-10-14-28-31(16-23)40-21-36(35(43)41-24-11-12-25(41)20-39(3)19-24)18-30(36)29-17-26(46-4)13-15-27(29)33(40)32(28)22-8-6-5-7-9-22/h10,13-17,22,24-25,30H,5-9,11-12,18-21H2,1-4H3,(H,37,42)/t24?,25?,30-,36-/m0/s1
• InChIKey: ZTTKEBYSXUCBSE-VSBZUFFNSA-N
• SMILES: CN1CC2CCC(C1)N2C(=O)[C@]34C[C@H]3C5=C(C=CC(=C5)OC)C6=C(C7=C(N6C4)C=C(C=C7)C(=O)NS(=O)(=O)N(C)C)C8CCCCC8

Beclabuvir（Cat No.:I005682）is a high-purity non-nucleoside inhibitor of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase, crucial for HCV replication. It binds to an allosteric site on the polymerase, disrupting viral RNA synthesis. Beclabuvir is widely studied for its role in combination antiviral therapies aimed at achieving sustained virologic response (SVR) in HCV patients. Its specificity and potent antiviral activity make it a valuable tool in exploring HCV drug resistance and optimizing therapeutic regimens. Beclabuvir supports advancements in antiviral research and the development of innovative HCV treatments.

Reference

[1]. Gentile I, et al. Beclabuvir for the treatment of hepatitis C. Expert Opin Investig Drugs. 2015;24(8):1111-21. 





[2]. Tatum H, et al. A randomized, placebo-controlled study of the NS5B inhibitor beclabuvir with peginterferon/ribavirin for HCV genotype 1. J Viral Hepat. 2015 Aug;22(8):658-64. 





[3]. Muir AJ, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA. 2015 May 5;313(17):1736-44.